Last reviewed · How we verify
TdaP vaccine SSI
The TdaP vaccine SSI works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, and pertussis.
The TdaP vaccine SSI works by stimulating the body's immune system to produce antibodies against diphtheria, tetanus, and pertussis. Used for Prevention of diphtheria, tetanus, and pertussis in individuals of all ages.
At a glance
| Generic name | TdaP vaccine SSI |
|---|---|
| Sponsor | Statens Serum Institut |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine contains inactivated diphtheria, tetanus, and pertussis antigens that are combined with a diphtheria toxoid. When administered, it triggers an immune response, producing antibodies that help protect against these bacterial infections. The vaccine is designed to provide long-term immunity against diphtheria, tetanus, and pertussis.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in individuals of all ages
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Influence of BCG on TDaP-IPV Vaccination (PHASE4)
- Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TdaP vaccine SSI CI brief — competitive landscape report
- TdaP vaccine SSI updates RSS · CI watch RSS
- Statens Serum Institut portfolio CI